PALO ALTO, Calif., Jan. 3 /PRNewswire/ --
CV Therapeutics, Inc. (Nasdaq: CVTX) and
Incyte Pharmaceuticals, Inc. (Nasdaq: INCY) announced that the American Heart
Association has selected CV Therapeutics' discovery of the role of the "good"
cholesterol-regulating gene, ABC1, as one of the top ten 1999 research
advances in heart disease and stroke. This discovery was presented at the
American Heart Association's 72nd Scientific Sessions and published in the
Journal of Clinical Investigation in 1999.
Through the use of Incyte's gene expression microarray technology along
with other techniques, scientists at CV Therapeutics, working with Incyte and
University of Washington, identified that ABC1 is a key gene involved in the
formation of high density lipoprotein (HDL), or "good" cholesterol. Richard
M. Lawn, Ph.D., Vice President, Discovery Research at CV Therapeutics and his
colleagues at CVT then demonstrated that increasing levels of this gene in
cultured cells in the laboratory enhances the removal of cholesterol from
cultured cells. These discoveries provided the first biological evidence
suggesting that drug therapies that increase the level of ABC1 might aid in
the removal of cholesterol from the body, holding the potential for reducing
the risk of heart disease among the general population.
According to the American Heart Association, the annual list was first
created in 1996 to highlight the achievements in basic and clinical research
that may have the greatest impact in improving the prevention and treatment of
cardiovascular disease, the nation's number one killer.
"The American Heart Association's recognition is testimony to the
potential this finding holds for discovering new therapeutic solutions for HDL
cholesterol management," said Louis G. Lange, M.D., Ph.D., Chairman and Chief
Executive Officer of CV Therapeutics. "This discovery demonstrates how
combining cardiovascular expertise along with the power of genomics and
microarray technology can lead to new drug discovery targets that could
potentially help the many people suffering from cardiovascular diseases."
This discovery also represented the first time gene expression microarray
analysis has been used to identify a defect associated with a human genetic
condition. This technique uses a micro-chip with thousands of genes covering
its surface. Microarray analysis dramatically reduces the amount of time
usually necessary to monitor the expression level of thousands of genes
concurrently. Scientists were able to pinpoint the faulty gene and its
encoded protein with the help of Incyte's Gene Album(TM) microarrays by
studying the activity of 60,000 genes from people with Tangier disease, a rare
genetic disorder that results in dangerously low levels of HDL, and an
increased risk for heart attack, against genes from an unaffected individual.
"This is a validation of the role of genomics in the understanding and
treatment of disease," said Randy Scott, President and Chief Scientific
Officer of Incyte Pharmaceuticals. "We are appreciative of the
acknowledgement by the American Heart Association and would welcome future
collaboration opportunities with CV Therapeutics."
The CV Therapeutics and Incyte collaboration is focused on creating gene
expression profiles of cardiovascular disease models. CV Therapeutics
contributes its molecular cardiology expertise and Incyte contributes its
genomics expertise to the collaboration.
In addition to historical information, this press release contains
forward-looking statements that involve risks and uncertainties, including,
but not limited to, uncertainties related to CV Therapeutics' early stage of
development and clinical trials. Actual results could differ materially.
Factors that could cause or contribute to such differences are more fully
discussed in CV Therapeutics' Prospectus dated October 6, 1999.
Except for the historical information contained herein, the matters set
forth in this press release, are forward-looking statements within the meaning
of the "safe harbor" provisions of the Private Securities Litigation Reform
Act of 1995. These forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially. For a
discussion of factors that may cause results to differ, see Incyte's SEC
reports, including its Annual Report on Form 10-Q for the quarter ended
September 30, 1999. Incyte disclaims any intent or obligation to update these
CV Therapeutics, Inc., headquartered in Palo Alto, CA, is a
biopharmaceutical company focused on applying molecular cardiology to the
discovery, development and commercialization of novel, small molecule drugs
for the treatment of cardiovascular diseases. CVT currently has three drug
candidates in clinical trials. Ranolazine, the first in a new class of drugs
known as partial fatty acid oxidation (pFOX) inhibitors for the potential
treatment of angina, is in Phase III clinical trials. CVT-510, for the
potential treatment of atrial arrhythmias, is in Phase II clinical trials. A
third product, CVT-124, for the potential treatment of congestive heart
failure (CHF), is in Phase II clinical trials. For more information, please
visit CV Therapeutics' web site at www.cvt.com.
Incyte Pharmaceuticals, Inc. is a leading provider of an integrated
platform of genomic technologies designed to aid in the understanding of the
molecular basis of disease. Incyte develops and markets genomic databases,
genomic data management software, microarray-based gene expression services,
related reagents and services. These products and services assist
pharmaceutical and biotechnology researchers with all phases of drug discovery
and development including gene discovery, understanding disease pathways,
identifying new disease targets and the discovery and correlation of gene
sequence variation to disease. For more information, visit Incyte's Web site
SOURCE CV Therapeutics, Inc.; Incyte Pharmaceuticals, Inc.